Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

José M. Gatell(Universitat de Barcelona), Nadine Ktorza, Jaime H. Vera(Brighton and Sussex Medical School), José Ignacio Bernardino(Hospital Universitario La Paz), Alan Winston, Mark Gompels, Els Caluwé(Ghent University Hospital), Andrea Giacomelli(ASST Fatebenefratelli Sacco), Christine Katlama(Université Paris Cité), Clotilde Allavena(Centre Hospitalier Universitaire de Nantes), María Saumoy(Bellvitge University Hospital), Julie Fox(National Health Service), J. Connault, Christoph Stephan(Goethe University Frankfurt), Coca Necsoi(Centre Hospitalier Universitaire de Saint-Pierre), Thierry Le Tourneau, Jean‐Michel Molina(Assistance Publique – Hôpitaux de Paris), Miresta Prévilon(Délégation Paris 7), Anton Pozniak, Graeme Moyle(Chelsea and Westminster Hospital), Véronique Reliquet, Yazdan Yazdanpanah(Inserm), Peré Domingo(Hospital de Sant Pau), Éric Florence(Instituut voor Tropische Geneeskunde), Linos Vandekerckhove(Ghent University Hospital), Stefan Eßer(Essen University Hospital), Julien Gras(Université Paris Cité), Mar Masiá(Universidad de Alcalá), Estebán Martínez(Instituto de Salud Carlos III), Laura Waters(Central and North West London NHS Foundation Trust), Maartje Van Frankenhuijsen, Lambert Assoumou(Inserm), Margaret Johnson(Duke University), Véronique Joly(ViiV Healthcare (United Kingdom)), Stéphane De Wit(Centre Hospitalier Universitaire de Saint-Pierre), Roland Landman, François Raffi, F. Raffi(Inserm), Juergen Rockstroh, Audrey Rodallec, Adriana Pinto Martinez(Sorbonne Université), Morane Cavellec, Fabienne Caby, Samuel Ferret, Hans-Jürgen Stellbrink(Universität Hamburg), Giovanni Guaraldi(University of Modena and Reggio Emilia)
Clinical Infectious Diseases
June 13, 2018
Cited by 48


Related Papers